Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Scilex Holding Company extends maturity date of Senior Secured Promissory Note with Oramed Pharmaceuticals Inc.
Jan 21, 2025
Contract Type
agreement
DallasBiotechnologyHealth CareMedicalTherapeutics
Description
Scilex Holding Company has signed an agreement to extend the maturity date of its Senior Secured Promissory Note issued to Oramed Pharmaceuticals Inc. from March 21, 2025 to December 31, 2025, which includes additional covenants with respect to the conduct of the Company’s business.
Company Information
Company
Nanoscope Therapeutics
Location
1312 BROWN TRAIL
Dallas, Texas, United States
About
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.
DallasBiotechnologyHealth CareMedicalTherapeutics